MDM2 and dedifferentiated liposarcoma: Moreover, a combination of the FGFR inhibitors erdafitinib and NVP-BGJ398 together with the MDM2 antagonist RG7388 was shown to be a promising strategy for the treatment of DDLPS and needs further investigation in clinical trials [55,119].